2016年6月毕业于上海交通大学医学院临床医学五年制（英文班）

2024年6月毕业于上海交通大学医学院附属仁济医院（肿瘤学-学术型硕士），研究方向为消化道肿瘤免疫治疗及耐药机制研究

2024年9月进入复旦大学附属肿瘤医院（影像医学与核医学-学术型博士），研究方向为卵巢肿瘤免疫微环境与代谢

Publications：

1.Zhang B, He L, et al. A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers. Sci Rep. 

2024 Jan 29;14(1):2367.  （共同一作）

2.Tang Y, Zhou C, Li Q, Cheng X, Huang T, Li F, He L, et al. Targeting depletion of myeloid-derived suppressor cells potentiates 

PD-L1 blockade efficacy in gastric and colon cancers. Oncoimmunology. 2022 Oct 13;11(1):2131084.  

3.Chen Y, Liao Y, Lam LM, He L, et al. Pretreatment biomarkersas prognostic predictors of survival in patients with Pancreatic 

Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio vs Platelet-to-lymphocyte 

ratio.Int J Med Sci.2020; 17(10):1449-1457. 

4. 何丽娜,成小姣等. PD-1/PD-L1 免疫检查点抑制剂联合胸腺肽α1 治疗恶性 肿瘤的临床疗效[J]. 中国医师杂志,2022,24(5):783-786. (IF: 2.54)

5. 何丽娜，楼伊云等. 慢性肾脏病患者肿瘤发病情况和相关危险因素[J]. 中 华肾脏病杂志, 2020, 36(6): 487-491 (IF:2.31)

6. He L, Zhang F, et al. Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report. Onco Targets Ther. 2020 Aug 27;13:8749-8756. (IF:4.1)

7. He L, Cheng X, et al. Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report. J Gastrointest Oncol. 2023 Dec 31;14(6):2617-2626.(IF:2.1)

8.Wu Q, He L(co-first author), et al. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report. Oncol Lett. 2022 Aug 12;24(4):339. (IF:2.9)